Zinc diethyldithiocarbamate does not have a defined pharmacological target as it is an industrial chemical and agrochemical. The compound is used as a rubber accelerator and vulcanization agent. It has a role as an antifungal agrochemical. As a chelating ligand, it can bind metal ions. Its primary applications are in the rubber industry and as an agricultural fungicide rather than as a therapeutic agent.

In vitro activity of zinc diethyldithiocarbamate has been studied as an antifungal agent. The compound exhibits antifungal activity and is used as an agrochemical. In research settings, the compound is used as a chelating agent and in rubber acceleration studies. Its activity is assessed in terms of fungicidal efficacy and rubber curing performance rather than direct pharmacological activity.

No specific in vivo pharmacological activity data have been documented for zinc diethyldithiocarbamate as a therapeutic agent. The compound is used primarily in the rubber industry and as an agrochemical. If used in animal studies, it would be administered for toxicological or agricultural research purposes. The compound can enter the body through the lungs, skin, and gastrointestinal tract.

For non-cellular assays, zinc diethyldithiocarbamate is characterized by standard analytical techniques including HPLC, NMR, and elemental analysis to confirm identity and purity. The compound can be evaluated for its chelating properties and rubber acceleration activity. Typical protocols involve dissolving the compound in appropriate solvents and analyzing by chromatographic methods. Purity: ≥99.0% by chelometric titration. Melting point: 178.0 to 182.0°C.

For in vitro cell-based studies, zinc diethyldithiocarbamate is not typically used as a direct test compound in mammalian cell culture. The compound is used in agricultural and industrial research. If handled in a biological laboratory context, appropriate safety precautions should be taken due to the zinc and sulfur content. Storage: room temperature (below 15°C in a cool, dry place).

For in vivo animal studies, zinc diethyldithiocarbamate may be used in toxicological studies. The compound can enter the body through the lungs, skin, and gastrointestinal tract. Intestinal absorption of zinc is controlled by zinc carrier protein CRIP. Dosing and administration should follow approved animal protocols.

Metabolism / Metabolites
Carbon disulfide and its major metabolite, 2-thiothiazolidin-4-carboxylic acid, are common metabolites of almost all dithiocarbamates. Significantly elevated concentrations of these compounds in urine have been observed under various exposure conditions and for different dithiocarbamates. Zinc can enter the body via the lungs, skin, and gastrointestinal tract. Intestinal absorption of zinc is regulated by the zinc carrier protein CRIP. Zinc can also bind to metallothioneins, thus helping to prevent excessive zinc absorption. Zinc is widely distributed in all tissues and tissue fluids, with higher concentrations in the liver, gastrointestinal tract, kidneys, skin, lungs, brain, heart, and pancreas. In the blood, zinc binds to carbonic anhydrase in erythrocytes and also to albumin, β2-macroglobulin, and amino acids in plasma. Albumin- and amino acid-bound zinc can diffuse across tissue membranes. Zinc is excreted in urine and feces. (L49)

---

Zinc diethyldithiocarbamate has a molecular weight of 361.90 and molecular formula C10H20N2S4Zn. It appears as a white to almost white powder to crystal with a melting point of 178.0 to 182.0°C. Purity: ≥99.0% by chelometric titration. Storage: room temperature (below 15°C in a cool, dry place). The compound is a dithiocarbamate salt and zinc molecular entity.

Toxicity Summary
Anemia is caused by excessive zinc absorption inhibiting the absorption of copper and iron, likely through competitive binding with intestinal mucosal cells. An imbalance in the binding levels of copper and zinc with copper-zinc superoxide dismutase is associated with amyotrophic lateral sclerosis (ALS). Gastric acid dissolves metallic zinc to form corrosive zinc chloride, which damages the gastric mucosa. Metal fume fever is thought to be an immune response following zinc inhalation. (L48, L49, A49) Toxicity Data
LD50: 142 mg/kg (oral, mouse) (T14) Non-human Toxicity Values Rabbit oral LD50: 400 mg/kg body weight Rat oral LD50: 3340 mg/kg Mouse oral LD50: 142 mg/kg

---

Zinc diethyldithiocarbamate has toxicological concerns. Anaemia results from the excessive absorption of zinc suppressing copper and iron absorption, most likely through competitive binding of intestinal mucosal cells. The compound is for research and industrial use only and not for human consumption. Standard laboratory safety practices should be followed.

Zinc diethyldithiocarbamate is a dithiocarbamate, specifically the zinc salt of diethyldithiocarbamate. It is an accelerator and activator for natural rubber and also has antifungal properties. It is a dithiocarbamate and a zinc molecular entity. It contains a diethyldithiocarbamate ion and a zinc ion (Zn²⁺). It is functionally related to diethyldithiocarbamate. Zinc dithiocarbamate, also known as zinc diethyldithiocarbamate salt, is a known copper and zinc chelating agent. It is also a skin sensitizer and allergen. Sensitivity to zinc dithiocarbamate can be identified through clinical patch testing. Zinc diethyldithiocarbamate is a standardized chemical allergen. The physiological effects of zinc diethyldithiocarbamate are achieved through increased histamine release and cell-mediated immune responses. Zinc diethyldithiocarbamate is chemically classified as an allergen. Zinc diethyldithiocarbamate is a zinc compound. Zinc is a metallic element with atomic number 30. Its most common form in nature is sphalerite. While excessive zinc is harmful, small amounts are essential for life because it is a cofactor for over 300 enzymes and is present in just as many transcription factors (L48, L49). It is a chelating agent used to remove toxic metals from tissues in humans and laboratory animals. It is the major metabolite of disulfiram. Drug Indications Disulfiram is approved for use in allergic skin patch testing, an auxiliary diagnostic test for allergic contact dermatitis (ACD) in individuals aged 6 years and older. Mechanism of Action Carbamates, when used alone, have a weak activation of estrogen- or progesterone-responsive reporter genes in breast and endometrial cancer cells. All carbamates reduce estradiol- or progesterone-induced reporter gene activity in breast and endometrial cancer cells. In whole-cell competitive binding assays, carbamates have limited ability to displace radiolabeled estrogen or progesterone from estrogen or progesterone receptors.

---

Zinc diethyldithiocarbamate (CAS 14324-55-1) is also known as zinc diethyldithiocarbamate, ethyl ziram, and diethyldithiocarbamic acid zinc salt. It is used as a rubber vulcanization accelerator, antifungal agrochemical, and chelating agent. No clinical trials or therapeutic approvals exist.

C10H20N2S4ZN

361.92

359.98

14324-55-1

26633

White powder

1,48 g/cm3

176.4ºC at 760 mmHg

172-176 °C

60.5ºC

1.1mmHg at 25°C

2.317

0

4

4

17

73

0

[Zn+2].[S-]C(N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])[H])=S.[S-]C(N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])[H])=S

RKQOSDAEEGPRER-UHFFFAOYSA-L

InChI=1S/2C5H11NS2.Zn/c2*1-3-6(4-2)5(7)8;/h2*3-4H2,1-2H3,(H,7,8);/q;;+2/p-2

zinc;N,N-diethylcarbamodithioate

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)